163 related articles for article (PubMed ID: 8091247)
1. Biologic therapy in patients receiving salvage treatment.
Bukowski RM
Semin Oncol; 1994 Aug; 21(4 Suppl 7):96-9. PubMed ID: 8091247
[TBL] [Abstract][Full Text] [Related]
2. Mucosal protection by cytokines.
Hofmeister CC; Stiff PJ
Curr Hematol Rep; 2005 Nov; 4(6):446-53. PubMed ID: 16232381
[TBL] [Abstract][Full Text] [Related]
3. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
5. New directions in hematologic biotherapy.
Groopman JE
Semin Hematol; 1989 Jul; 26(3 Suppl 3):1-6. PubMed ID: 2477903
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
7. Biologic response modifiers in chronic hepatitis C.
Carreño V; Quiroga JA
J Hepatol; 1995; 22(1 Suppl):122-6. PubMed ID: 7541408
[TBL] [Abstract][Full Text] [Related]
8. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
[TBL] [Abstract][Full Text] [Related]
9. Cytokine therapy for hematological malignancies.
Ezaki K; Tsuzuki M
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():182-94. PubMed ID: 9210900
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic use of myelopoietic growth factors in children after myelosuppressive and myeloablative therapy.
Satwani P; Bessmertny O; Morris E; Cairo MS
Curr Hematol Rep; 2003 Nov; 2(6):480-90. PubMed ID: 14561392
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa and high-dose chemotherapy.
Henry DH
Semin Oncol; 1998 Jun; 25(3 Suppl 7):54-7. PubMed ID: 9671332
[TBL] [Abstract][Full Text] [Related]
13. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry.
de la Rubia J; de Arriba F; Arbona C; Pascual MJ; Zamora C; Insunza A; Martínez D; Paniagua C; Díaz MA; Sanz MA
Haematologica; 2008 May; 93(5):735-40. PubMed ID: 18387976
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
Page AV; Liles WC
Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
[TBL] [Abstract][Full Text] [Related]
19. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
